GB201813677D0 - Calcitonin mimetics for treating diseases and disorders - Google Patents
Calcitonin mimetics for treating diseases and disordersInfo
- Publication number
- GB201813677D0 GB201813677D0 GBGB1813677.0A GB201813677A GB201813677D0 GB 201813677 D0 GB201813677 D0 GB 201813677D0 GB 201813677 A GB201813677 A GB 201813677A GB 201813677 D0 GB201813677 D0 GB 201813677D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- disorders
- treating diseases
- calcitonin mimetics
- calcitonin
- mimetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000055006 Calcitonin Human genes 0.000 title 1
- 108060001064 Calcitonin Proteins 0.000 title 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title 1
- 229960004015 calcitonin Drugs 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813677.0A GB201813677D0 (en) | 2018-08-22 | 2018-08-22 | Calcitonin mimetics for treating diseases and disorders |
| PCT/EP2019/072535 WO2020039052A1 (en) | 2018-08-22 | 2019-08-22 | Calcitonin mimetics for treating diseases and disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813677.0A GB201813677D0 (en) | 2018-08-22 | 2018-08-22 | Calcitonin mimetics for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201813677D0 true GB201813677D0 (en) | 2018-10-03 |
Family
ID=63668229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1813677.0A Ceased GB201813677D0 (en) | 2018-08-22 | 2018-08-22 | Calcitonin mimetics for treating diseases and disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201813677D0 (en) |
| WO (1) | WO2020039052A1 (en) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| GB2218102B (en) * | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5698521A (en) * | 1995-04-04 | 1997-12-16 | Zymogenetics, Inc. | Native calcitonin mimetics |
| US5698672A (en) * | 1995-04-04 | 1997-12-16 | Zymogenetics, Inc. | Synthetic calcitonin mimetics |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| DK1005526T3 (en) | 1997-04-16 | 2011-02-07 | Unigene Lab Inc | Direct expression of peptides in culture medium |
| JP2002531518A (en) | 1998-12-04 | 2002-09-24 | プロヴァリス・ユーケー・リミテッド | Insulin-containing pharmaceutical composition |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| WO2004084870A1 (en) | 2003-03-28 | 2004-10-07 | Sigmoid Biotechnologies Limited | Solid oral dosage form containing seamless microcapsules |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| KR101215821B1 (en) * | 2003-06-30 | 2012-12-28 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| ES2436152T3 (en) | 2003-07-23 | 2013-12-27 | Novartis Ag | Use of calcitonin in osteoarthritis |
| US20070172517A1 (en) | 2003-09-17 | 2007-07-26 | Ben-Sasson Shmuel A | Compositions capable of facilitation penetration across a biological barrier |
| US20080200563A1 (en) | 2004-07-22 | 2008-08-21 | Thiomatrix Forschungs- Und Beratungs- Gmbh | Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| CA2613471C (en) | 2005-06-24 | 2016-09-06 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| AU2006288703B2 (en) | 2005-09-06 | 2011-09-22 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| ATE515260T1 (en) | 2006-03-13 | 2011-07-15 | Advanced In Vitro Cell Technologies S L | STABLE NANOCAPSULE SYSTEMS FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS |
| MX2008012678A (en) | 2006-04-07 | 2008-12-17 | Merrion Res Iii Ltd | Solid oral dosage form containing an enhancer. |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| MX351092B (en) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | PEPTIDE ANALOGS FOR TREATING DISEASES and DISORDERS. |
| EP3068796B1 (en) | 2013-11-14 | 2018-01-31 | KeyBioscience AG | Calcitonin mimetics for treating diseases and disorders |
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
-
2018
- 2018-08-22 GB GBGB1813677.0A patent/GB201813677D0/en not_active Ceased
-
2019
- 2019-08-22 WO PCT/EP2019/072535 patent/WO2020039052A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020039052A1 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4218640T3 (en) | Systems for the treatment of disease states and disorders | |
| IL269174B1 (en) | Methods for treating complement-mediated diseases and disorders | |
| HRP20190356T1 (en) | Calcitonin mimetics for treating diseases and disorders | |
| PT3810128T (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
| IL275985A (en) | Compositions and methods for treating retinal disorders | |
| IL253026A0 (en) | Calcitonin analogues for treating diseases and disorders | |
| GB201704429D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| PT3897655T (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| GB201813677D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| IL284029B1 (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| GB201707955D0 (en) | Dual amylin and calcitonin receptor agonists for treating diseases and disorders | |
| GB201711838D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| GB201704355D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| IL276697A (en) | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders | |
| GB201414706D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| GB201808159D0 (en) | Therapeutic compositions for treating neurocognative, neurodevelopmental and psychocognitive disorders | |
| GB201807611D0 (en) | Methods for assessing and treating complement-related disorders | |
| SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
| GB201902790D0 (en) | Methods for assessing and treating complement-related disorders | |
| HK40021785A (en) | Methods for treating complement-mediated diseases and disorders | |
| GB201320112D0 (en) | Calcitonin Mimetics for treating diseases and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |